Keyphrases
Ramipril
100%
Acute Anterior Myocardial Infarction
100%
Plasminogen Activator inhibitor-1 (PAI-1)
85%
Tissue Plasminogen Activator (t-PA)
42%
Placebo
28%
Plasma Parameters
28%
Day 14
28%
ACE Inhibitors
28%
Thrombosis
14%
Healing
14%
Fibrinolysis
14%
Activity Level
14%
Clinical Benefit
14%
Acute Myocardial Infarction
14%
Renin-angiotensin System
14%
Left Ventricular Dysfunction
14%
Patient Selection
14%
Regulatory Pathways
14%
Clinical Characteristics
14%
Placebo Groups
14%
Symptom Onset
14%
Double-blind Placebo-controlled Trial
14%
Ischemic Events
14%
Vascular Tone
14%
Long-term Administration
14%
Recovery Phase
14%
Recurrent Myocardial Infarction
14%
Myocardial Infarction Patients
14%
Antigen Levels
14%
Angina Pectoris
14%
Plasma Tissue
14%
Atherosclerotic Process
14%
Afterload Reduction
14%
ACE Inhibitor Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ramipril
100%
Fibrinolytic Agent
100%
Anterior Myocardial Infarction
100%
Plasminogen Activator Inhibitor 1
85%
Placebo
57%
Dipeptidyl Carboxypeptidase Inhibitor
42%
Tissue Plasminogen Activator
42%
Heart Infarction
14%
Acute Heart Infarction
14%
Heart Left Ventricle Failure
14%
Unstable Angina Pectoris
14%
Thrombosis
14%
Renin
14%
Angiotensin
14%